| atezolizumab based treatment |
| atezolizumab plus carboplatin plus nab-paclitaxel | atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide |
| es-BC - TNBC - NA - all population 5 | | |
Comparator:
vs carboplatin plus nab-paclitaxel; vs placebo plus SoC;
Risk of bias:
low;
some concerns;
high;
NA;